We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sulforadex in Healthy Human Males MAD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02055716
First Posted: February 5, 2014
Last Update Posted: February 10, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Evgen Pharma
  Purpose
To determine the safety and tolerability of multiple doses of Sulforadex® in healthy male volunteers over 7 days with qd or bid dosing

Condition Intervention Phase
Prostate Cancer Drug: Sulforadex Drug: alpha-cyclodextrin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects Following Daily Dosing for 7 Days

Resource links provided by NLM:


Further study details as provided by Evgen Pharma:

Primary Outcome Measures:
  • Number of participants with adverse events [ Time Frame: 7 days ]
    Safety assessments will include standard laboratory safety tests (haematology, biochemistry, coagulation and urinalysis), vital signs, physical examinations, 12-lead ECG, telemetry and AE monitoring.


Secondary Outcome Measures:
  • Area under the plasma concentration versus time curve (AUC) of sulforaphane [ Time Frame: time 0, 30 min 1 2 4 8 12 & 24 hrs post dose on days 1,2 & 7 ]

    Plasma sulforaphane concentrations will be measured by LCMS/MS assay.

    • Area under the plasma concentration-time curve from zero to time t of the last measured concentration above the limit of quantification (AUC0-t).



Enrollment: 18
Study Start Date: January 2014
Study Completion Date: May 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: alpha-cyclodextrin
A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
Drug: alpha-cyclodextrin
Experimental: Sulforadex
100mg or 300mg size 00 acid resistant HPMC capsules
Drug: Sulforadex
Other Name: Stabilised sulforaphane

Detailed Description:
This study will be conducted in a randomised, double-blind, placebo-controlled design with multiple ascending doses of Sulforadex® administered qd [once daily] or bid [twice daily]) to healthy male subjects between 18 to 45 years of age.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is a healthy male of any race aged 18 to 45 years, inclusive, at screening.
  2. Subject has a BMI of 18 - 25 kg/m2 inclusive at screening.
  3. Subjects must agree to use acceptable methods of contraception,
  4. Subjects should not donate sperm from the time of the first administration of treatment or study medication until 3 months following administration of the last treatment or dose of study medication.
  5. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the ICF prior to undergoing any study-related procedures.

Exclusion Criteria:

  1. All subjects must refrain from eating brassica vegetables or using brassica containing supplements for at least 7 days prior to the drug administration. Brassica vegetables include cabbage, cauliflower, horseradish, landcress, Ethiopian mustard, kale, collard greens, Chinese broccoli, brussels sprouts, Kohlrabi broccoli, broccoli flower, broccoli romanesco, wild broccoli, bok choy, Komatsuna, mizuna, rapini, flowering cabbage, Chinese cabbage, Napa cabbage, turnip root, rutabaga, canola/rape seed, Siberian kale, wrapped heart mustard cabbage, mustard seed (brown, black, white), tatsoi, rocket (arugula), garden cress, water cress, radish, daikon and wasabi.
  2. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion.
  3. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.
  4. ECG abnormalities in the standard 12-lead ECG (at screening) which in the opinion of the Investigator is clinically relevant or will interfere with the ECG analysis.
  5. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, psychiatric, or other disease.
  6. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti Hepatitis core antibody (anti HBc Ig G [and anti HBc IgM if IgG is positive], Hepatitis C virus antibodies (anti HCV), and human immunodeficiency virus HIV 1 and 2 antibodies (anti HIV 1/2).
  7. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and methadone) or from the alcohol breath test at screening and on admission (Day -1).
  8. History or clinical evidence of alcohol or drug abuse.
  9. Mentally handicapped.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02055716


Locations
United Kingdom
Richmond Pharmacology Limited
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
Evgen Pharma
Investigators
Principal Investigator: Jörg Täubel, MD FFPM Richmond Pharmacology Limited
  More Information

Responsible Party: Evgen Pharma
ClinicalTrials.gov Identifier: NCT02055716     History of Changes
Other Study ID Numbers: EVG002N
First Submitted: January 29, 2014
First Posted: February 5, 2014
Last Update Posted: February 10, 2015
Last Verified: February 2015


To Top